深度聚焦！艾迪康控股(09860)持续回购股份 6月13日再斥资15.57万港元回购1.9万股

艾迪康控股(09860)持续回购股份 6月13日再斥资15.57万港元回购1.9万股

香港，2024年6月14日 - 艾迪康控股(09860)今日发布公告，称公司于6月13日回购了1.9万股股份，耗资约15.57万港元。

此次回购详情如下：

• 回购价格：每股8.15-8.3港元
• 回购股份数量：1.9万股
• 回购总金额：约15.57万港元

艾迪康控股近期回购情况

• 自2024年5月31日启动回购计划以来，艾迪康控股已累计回购约435.13万股，耗资约5亿港元。
• 公司表示，回购股份是公司回馈股东、提升公司价值的重要举措。

市场分析

• 艾迪康控股近期回购力度加大，显示出公司对自身发展前景的信心。
• 公司股价近期有所回落，回购有利于提振投资者信心。
• 有分析人士认为，艾迪康控股未来可能会继续回购股份，以进一步提升公司价值。

艾迪康控股(09860)简介

艾迪康控股是一家主要从事设计、制造和销售精密模具及相关产品的香港公司。公司业务遍及全球，主要客户包括知名消费电子产品制造商。

以下是一些关于艾迪康控股(09860)回购股份的额外信息：

• 艾迪康控股回购股份的资金来源为公司自有资金。
• 回购股份将注销。
• 艾迪康控股回购计划将于2024年8月1日到期。

请注意：

• 本文仅供参考，不构成任何投资建议。
• 本文中的信息可能存在误差或遗漏，恕不承担任何责任。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.